![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
| Item Type: | Letter |
|---|---|
| Title: | Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma |
| Creators Name: | Dang, N.H. and Ogura, M. and Castaigne, S. and Fayad, L.E. and Jerkeman, M. and Radford, J. and Pezzutto, A. and Bondarenko, I. and Stewart, D.A. and Shnaidman, M. and Sullivan, S. and Vandendries, E. and Tobinai, K. and Ramchandren, R. and Hamlin, P.A. and Giné, E. and Ando, K. |
| Keywords: | Inotuzumab Ozogamicin, B-Cell Non-Hodgkin Lymphoma, CD22+, Antibody-Drug Conjugate, Rituximab |
| Source: | British Journal of Haematology |
| ISSN: | 0007-1048 |
| Publisher: | Wiley-Blackwell |
| Volume: | 182 |
| Number: | 4 |
| Page Range: | 583-586 |
| Date: | August 2018 |
| Official Publication: | https://doi.org/10.1111/bjh.14820 |
| External Fulltext: | View full text on PubMed Central |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
